Table 6.
Summary of Base-case Cost-effectiveness Results across Different Study Perspectives
| N | Mean Costs | Mean QALYs | Incremental Costs | Incremental QALYs | ICER | |
|---|---|---|---|---|---|---|
| Societal | ||||||
| AAT | 10 | $14,308.00 | 0.74 | $4574 | −0.09 | AAT is dominated by TE/I |
| TE/I | 9 | $9734.00 | 0.83 | |||
| MOH | ||||||
| AAT | 18 | $4998.00 | 0.74 | $2664.00 | −0.09 | AAT is dominated by TE/I |
| TE/I | 13 | $2335.00 | 0.83 | |||
n, number of patients.